At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating Capecitabine, Laboratory Biomarker Analysis, and 2 other interventions for Colon Adenocarcinoma and 7 related conditions. Completed, enrolled 42 participants across 2 sites.
Detailed Summary
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine may be a better treatment for colorectal cancer.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given PO
Correlative studies